2026-10-14T07:23:46Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34032612 2026-09-30T13:25:56Z category_19 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis.docx Zhe Wang (41178) Bo Shao (1480513) Danxue Huang (15889565) Liyuan Ke (14140594) Pharmacology efficacy FGFR inhibitors meta-analysis safety systematic review urothelial carcinoma Introduction<p>We reviewed the clinical studies on fibroblast growth factor receptor (FGFR) inhibitors for the treatment of urothelial carcinoma to conduct the meta-analysis of clinical efficacy and safety, aiming to provide more precise treatment options for patients with FGFR alterations.</p>Method<p>We performed the literature search and screening, then calculated and analyzed using the STATA 14.0 software and Review Manager 5.3 software.</p>Results<p>A total of 1528 patients from seventeen studies focusing on seven different FGFR inhibitors were collected. The efficacy analysis indicated the pooled objective response rate (ORR) was 32% (95% CI 26% to 39%) and the pooled disease control rate (DCR) was 64% (95% CI 53% to 75%) for patients with FGFR alterations treated with FGFR inhibitors. The pooled ORR and DCR of second-generation FGFR inhibitors were both significantly higher than those of first-generation FGFR inhibitors (ORR: 0.35, 95% CI 0.29 to 0.41 versus 0.07, 95% CI 0.02 to 0.16, p < 0.001; DCR: 0.68, 95% CI 0.61 to 0.75 versus 0.27, 95% CI 0.16 to 0.40, p < 0.001). The safety analysis indicated any-grade TRAEs were comparable between first- and second-generation FGFR inhibitors, but grade ≥3 TRAEs were significantly less frequent with second-generation FGFR inhibitors versus first-generation FGFR inhibitors (0.49, 95% CI 0.40 to 0.57 versus 0.67, 95% CI 0.57 to 0.76; p = 0.006). The common target toxicities associated with FGFR inhibitors, such as hyperphosphatemia, stomatitis and PPES, were more frequently occurred in second-generation FGFR inhibitors compared to first-generation FGFR inhibitors.</p>Conclusion<p>The second-generation FGFR inhibitors have advantages in both efficacy and safety, but special adverse reactions still require additional attention.</p> 2026-09-30T13:25:56Z Dataset Dataset 10.3389/fphar.2026.1850131.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Efficacy_and_safety_of_first-_versus_second-generation_fibroblast_growth_factor_receptor_FGFR_inhibitors_in_advanced_or_metastatic_urothelial_carcinoma_with_FGFR_alterations_a_systematic_review_and_meta-analysis_docx/34032612 CC BY 4.0